192 related articles for article (PubMed ID: 37415627)
21. 'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization.
Müller M; Gfeller D; Coukos G; Bassani-Sternberg M
Front Immunol; 2017; 8():1367. PubMed ID: 29104575
[TBL] [Abstract][Full Text] [Related]
22. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.
Maeurer MJ; Gollin SM; Storkus WJ; Swaney W; Karbach J; Martin D; Castelli C; Salter R; Knuth A; Lotze MT
Clin Cancer Res; 1996 Apr; 2(4):641-52. PubMed ID: 9816214
[TBL] [Abstract][Full Text] [Related]
23. In silico analysis of MHC-I restricted epitopes of Chikungunya virus proteins: Implication in understanding anti-CHIKV CD8(+) T cell response and advancement of epitope based immunotherapy for CHIKV infection.
Pratheek BM; Suryawanshi AR; Chattopadhyay S; Chattopadhyay S
Infect Genet Evol; 2015 Apr; 31():118-26. PubMed ID: 25643869
[TBL] [Abstract][Full Text] [Related]
24. DeepNetBim: deep learning model for predicting HLA-epitope interactions based on network analysis by harnessing binding and immunogenicity information.
Yang X; Zhao L; Wei F; Li J
BMC Bioinformatics; 2021 May; 22(1):231. PubMed ID: 33952199
[TBL] [Abstract][Full Text] [Related]
25. Hepatobiliary Tumor Organoids Reveal HLA Class I Neoantigen Landscape and Antitumoral Activity of Neoantigen Peptide Enhanced with Immune Checkpoint Inhibitors.
Wang W; Yuan T; Ma L; Zhu Y; Bao J; Zhao X; Zhao Y; Zong Y; Zhang Y; Yang S; Qiu X; Shen S; Wu R; Wu T; Wang H; Gao D; Wang P; Chen L
Adv Sci (Weinh); 2022 Aug; 9(22):e2105810. PubMed ID: 35665491
[TBL] [Abstract][Full Text] [Related]
26. Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display.
Wickström SL; Lövgren T; Volkmar M; Reinhold B; Duke-Cohan JS; Hartmann L; Rebmann J; Mueller A; Melief J; Maas R; Ligtenberg M; Hansson J; Offringa R; Seliger B; Poschke I; Reinherz EL; Kiessling R
Front Immunol; 2019; 10():2766. PubMed ID: 31921104
[TBL] [Abstract][Full Text] [Related]
27. The use of Epstein-Barr virus-transformed B lymphocyte cell lines in a peptide-reconstitution assay: identification of CEA-related HLA-A*0301-restricted potential cytotoxic T-lymphocyte epitopes.
Bremers AJ; van der Burg SH; Kuppen PJ; Kast WM; van de Velde CJ; Melief CJ
J Immunother Emphasis Tumor Immunol; 1995 Aug; 18(2):77-85. PubMed ID: 8574469
[TBL] [Abstract][Full Text] [Related]
28. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
29. Elevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genes.
Castro A; Ozturk K; Pyke RM; Xian S; Zanetti M; Carter H
BMC Med Genomics; 2019 Jul; 12(Suppl 6):107. PubMed ID: 31345234
[TBL] [Abstract][Full Text] [Related]
30. Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy.
Zhang X; Qi Y; Zhang Q; Liu W
Biomed Pharmacother; 2019 Dec; 120():109542. PubMed ID: 31629254
[TBL] [Abstract][Full Text] [Related]
31. Identification of human MHC-I HPV18 E6/E7-specific CD8 + T cell epitopes and generation of an HPV18 E6/E7-expressing adenosquamous carcinoma in HLA-A2 transgenic mice.
Peng S; Xing D; Ferrall L; Tsai YC; Hung CF; Wu TC
J Biomed Sci; 2022 Oct; 29(1):80. PubMed ID: 36224625
[TBL] [Abstract][Full Text] [Related]
32. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
Hartmaier RJ; Charo J; Fabrizio D; Goldberg ME; Albacker LA; Pao W; Chmielecki J
Genome Med; 2017 Feb; 9(1):16. PubMed ID: 28231819
[TBL] [Abstract][Full Text] [Related]
33. [Induction of specific CD8(+) T cells against hepatocellular carcinoma-associated neoantigens].
Wang YM; Zhao BH; Chen K; Li ZJ; Qu CF
Zhonghua Zhong Liu Za Zhi; 2019 Jun; 41(6):429-434. PubMed ID: 31216828
[No Abstract] [Full Text] [Related]
34. Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy.
Plewa N; Poncette L; Blankenstein T
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822673
[TBL] [Abstract][Full Text] [Related]
35. Impact of Micropolymorphism Outside the Peptide Binding Groove in the Clinically Relevant Allele HLA-C*14 on T Cell Responses in HIV-1 Infection.
Chikata T; Paes W; Kuse N; Partridge T; Gatanaga H; Zhang Y; Kuroki K; Maenaka K; Ternette N; Oka S; Borrow P; Takiguchi M
J Virol; 2022 May; 96(10):e0043222. PubMed ID: 35475667
[TBL] [Abstract][Full Text] [Related]
36. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
[TBL] [Abstract][Full Text] [Related]
37. Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay.
Kuzushima K; Hayashi N; Kimura H; Tsurumi T
Blood; 2001 Sep; 98(6):1872-81. PubMed ID: 11535524
[TBL] [Abstract][Full Text] [Related]
38. Mapping cross-clade HIV-1 vaccine epitopes using a bioinformatics approach.
De Groot AS; Jesdale B; Martin W; Saint Aubin C; Sbai H; Bosma A; Lieberman J; Skowron G; Mansourati F; Mayer KH
Vaccine; 2003 Oct; 21(27-30):4486-504. PubMed ID: 14505932
[TBL] [Abstract][Full Text] [Related]
39. Identification of Mutated Peptides in Bladder Cancer From Exomic Sequencing Data Reveals Negative Correlation Between Mutation-Specific Immunoreactivity and Inflammation.
Wang C; Ding Y; Liu Y; Zhang Q; Xu S; Xia L; Duan H; Wang S; Ji P; Huang W; Zhao G; Cao Z; Shen H; Wang Y
Front Immunol; 2020; 11():576603. PubMed ID: 33329543
[TBL] [Abstract][Full Text] [Related]
40. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
Fehlings M; Jhunjhunwala S; Kowanetz M; O'Gorman WE; Hegde PS; Sumatoh H; Lee BH; Nardin A; Becht E; Flynn S; Ballinger M; Newell EW; Yadav M
J Immunother Cancer; 2019 Sep; 7(1):249. PubMed ID: 31511069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]